Paper42865026PubMed
Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.
Guo Y and 22 others. Liver Int, 2026.
Cite this record
ConductScience Library. Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. Papers, record 42865026. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42865026
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.
- Journal
- Liver Int
- Year
- 2026
- Publication types
- Journal Article, Clinical Trial, Phase II, Randomized Controlled Trial
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Antiviral Agents | Major topic |
| Hepatitis B virus | Major topic |
| Humans | |
| Double-Blind Method | |
| Male | |
| Adult | |
| Female | |
| Middle Aged | |
| Hepatitis B Surface Antigens | |
| Treatment Outcome | |
| DNA, Viral | |
| Benzoxepins | |
| Pyridines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Akeylink Biotechnology Co. Ltd. | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06263959 | A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B | Derived from the trial | Yes |
Source ClinicalTrials.gov
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33099752 | Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. | Hepatol Int | 2020 | https://conductscience.org/library/papers/33099752 | PubMed |
| 2 | 36453086 | Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon. | Liver Int | 2023 | https://conductscience.org/library/papers/36453086 | PubMed |
| 3 | 35092743 | Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. | J Hepatol | 2022 | https://conductscience.org/library/papers/35092743 | PubMed |
| 4 | 41107676 | Combination therapies for chronic hepatitis B in the era of emerging novel drugs. | Hepatol Int | 2026 | https://conductscience.org/library/papers/41107676 | PubMed |
| 5 | 33889654 | Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients. | Open Forum Infect Dis | 2020 | https://conductscience.org/library/papers/33889654 | PubMed |
| 6 | 36089112 | Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. | Bioorg Med Chem Lett | 2022 | https://conductscience.org/library/papers/36089112 | PubMed |
| 7 | 21410068 | Application of interferon response-related gene array to the antiviral treatment outcome in chronic hepatitis C. | Hepatogastroenterology | 2010 | https://conductscience.org/library/papers/21410068 | PubMed |
| 8 | 36727229 | [Clinical effect and influencing factors of pegylated interferon alfa-2a and entecavir monotherapy among children with HBeAg-positive chronic hepatitis B based on a real-world study]. | Zhonghua Gan Zang Bing Za Zhi | 2022 | https://conductscience.org/library/papers/36727229 | PubMed |
| 9 | 33486874 | Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. | Liver Int | 2021 | https://conductscience.org/library/papers/33486874 | PubMed |
| 10 | 34371538 | [Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance]. | Zhonghua Gan Zang Bing Za Zhi | 2021 | https://conductscience.org/library/papers/34371538 | PubMed |
| 11 | 34435408 | Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials. | J Viral Hepat | 2021 | https://conductscience.org/library/papers/34435408 | PubMed |
| 12 | 34593151 | Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. | Clin Liver Dis | 2021 | https://conductscience.org/library/papers/34593151 | PubMed |
| 13 | 19338056 | Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. | Hepatology | 2009 | https://conductscience.org/library/papers/19338056 | PubMed |
| 14 | 42865026 | Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. | Liver Int | 2026 | https://conductscience.org/library/papers/42865026 | PubMed |
| 15 | 36408671 | A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon. | Clin Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36408671 | PubMed |
| 16 | 21994680 | Antiviral treatment of chronic hepatitis B virus (HBV) infections. | Viruses | 2010 | https://conductscience.org/library/papers/21994680 | PubMed |
| 17 | 34225435 | [Clinical analysis of four cases of HBsAg seroconversion in patients with HBeAg-positive chronic hepatitis B after receiving interferon alpha therapy]. | Zhonghua Gan Zang Bing Za Zhi | 2021 | https://conductscience.org/library/papers/34225435 | PubMed |
| 18 | 35257963 | Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. | Virol Sin | 2022 | https://conductscience.org/library/papers/35257963 | PubMed |
| 19 | 33896094 | Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. | Liver Int | 2021 | https://conductscience.org/library/papers/33896094 | PubMed |
| 20 | 25733157 | The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. | J Hepatol | 2015 | https://conductscience.org/library/papers/25733157 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42865026 | Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. | Liver Int | 2026 | https://conductscience.org/library/papers/42865026 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42865026
GET https://conductscience.org/api/papers/v1/42865026/authors?page=2